ORAL C5A RECEPTOR ANTAGONIST CCX168 IN A PHASE 2 CLINICAL TRIAL IN ANCA-ASSOCIATED RENAL VASCULITIS

被引：0
|
作者：
Bekker, Pirow [1 ]
Potarca, Antonia [1 ]
Dairaghi, Daniel [1 ]
Miao, Shichang [1 ]
Powers, Jay P. [1 ]
Jaen, Juan C. [1 ]
Schall, Thomas J. [1 ]
机构：
[1] Chemocentryx Inc, Mountain View, CA USA
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2012年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
引用
收藏
页码：419 / 420
页数：2
相关论文
共 41 条
  • [31] Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial
    Tak, Paul P.
    Balanescu, Andra
    Tseluyko, Vira
    Bojin, Silvia
    Drescher, Edit
    Dairaghi, Dan
    Miao, Shichang
    Marchesin, Vittorio
    Jaen, Juan
    Schall, Thomas J.
    Bekker, Pirow
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (03) : 337 - 344
  • [32] A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement
    Mehta, Rohtesh. S. S.
    Ali, Haris
    Dai, Yang
    Yao, Bert
    Overman, Bethany
    Ratanatharathorn, Voravit
    Gill, Saar
    Socie, Gerard
    Anderson, Kevin
    Cahn, Jean Yves
    Mujeebuddin, Arshad
    Champlin, Richard
    Shpall, Elizabeth
    Holtan, Shernan. G. G.
    Alousi, Amin
    BONE MARROW TRANSPLANTATION, 2023, 58 (09) : 991 - 999
  • [33] A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement
    Rohtesh S. Mehta
    Haris Ali
    Yang Dai
    Bert Yao
    Bethany Overman
    Voravit Ratanatharathorn
    Saar Gill
    Gerard Socié
    Kevin Anderson
    Jean Yves Cahn
    Arshad Mujeebuddin
    Richard Champlin
    Elizabeth Shpall
    Shernan G. Holtan
    Amin Alousi
    Bone Marrow Transplantation, 2023, 58 : 991 - 999
  • [34] Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Avacopan, a Small-Molecule Complement C5a Receptor Antagonist, for the Treatment of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis
    Miao, Shichang
    Suso, Pablo
    Furst, John A.
    Hudson, Matthew G.
    Trivedi, Ashit
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (09): : 1000 - 1010
  • [35] Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)
    Charles, Pierre
    Terrier, Benjamin
    Perrodeau, Elodie
    Cohen, Pascal
    Faguer, Stanislas
    Huart, Antoine
    Hamidou, Mohamed
    Agard, Christian
    Bonnotte, Bernard
    Samson, Maxime
    Karras, Alexandre
    Jourde-Chiche, Noemie
    Lifermann, Francois
    Gobert, Pierre
    Hanrotel-Saliou, Catherine
    Godmer, Pascal
    Martin-Silva, Nicolas
    Pugnet, Gregory
    Matignon, Marie
    Aumaitre, Olivier
    Viallard, Jean-Francois
    Maurier, Francois
    Meaux-Ruault, Nadine
    Riviere, Sophie
    Sibilia, Jean
    Puechal, Xavier
    Ravaud, Philippe
    Mouthon, Luc
    Guillevin, Loic
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (08) : 1144 - 1150
  • [36] Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2) (vol 77, pg 1143, 2018)
    Charles, P.
    Terrier, B.
    Perrodeau, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (09) : E101 - E101
  • [37] Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial
    Merkel, Peter A.
    Jayne, David R.
    Wang, Chao
    Hillson, Jan
    Bekker, Pirow
    JMIR RESEARCH PROTOCOLS, 2020, 9 (04):
  • [38] Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study) A Randomized Controlled Trial
    Tapson, Victor F.
    Jing, Zhi-Cheng
    Xu, Kai-Feng
    Pan, Lei
    Feldman, Jeremy
    Kiely, David G.
    Kotlyar, Eugene
    McSwain, C. Shane
    Laliberte, Kevin
    Arneson, Carl
    Rubin, Lewis J.
    CHEST, 2013, 144 (03) : 952 - 958
  • [39] Effect of MUC5b Genetic Polymorphism on Response to Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986020 in a Phase 2 Clinical Trial in Idiopathic Pulmonary Fibrosis
    Minnich, A.
    Yang, M.
    Du, S.
    Soule, B.
    Luo, Y.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [40] A phase 2a proof of concept clinical trial to evaluate ZPL-3893787 (ZPL-389), a potent, oral histamine H4 receptor antagonist for the treatment of moderate to severe atopic dermatitis (AD) in adults
    Werfel, T.
    Lynch, V
    Asher, A.
    Tsianakas, A.
    Gupta, B.
    Sarmiento, R.
    Ploszczuk, A.
    Kuna, P.
    Majorek-Olechowska, B.
    Cimoszko, B.
    Nikkels, A.
    Hofman, T.
    Staubach, P.
    Breuer, K.
    Gawlik, A.
    Buczylko, K.
    Morren, M-A
    Layton, G.
    Yeadon, M.
    Whitlock, L.
    Purkins, L.
    Liu, W.
    Osterloh, I
    Jimenez, P.
    ALLERGY, 2016, 71 : 95 - 95
12345